The Food and Drug Administration anticipates a significant increase in applications for treatments targeting rare diseases following the unveiling of a new approval pathway for customized therapies, agency officials said Monday.
The proposed system, detailed in preliminary guidelines released by the FDA, aims to address the challenges of developing treatments for conditions affecting compact patient populations, often deemed unprofitable by the pharmaceutical industry. The new pathway is designed for “bespoke therapies” that have been tested in limited numbers of patients, a departure from traditional drug approval processes that rely on large-scale clinical trials.
“This proves our priority to remove barriers and exercise regulatory flexibility to encourage scientific advances and deliver more cures and meaningful treatments for patients suffering from rare diseases,” FDA Commissioner Marty Makary stated in a public release. The agency specifically highlighted gene editing as a potential application of the new approach, but indicated it could extend to other drugs and therapies as well.
A senior FDA official, speaking to reporters, predicted, “We anticipate that we’re going to get a flood of applications for treatments of rare diseases.”
The move has been lauded by patient advocates and researchers focused on rare diseases, who have long argued that the existing regulatory framework is ill-suited to their needs. The FDA’s action comes as the agency explores new methods for approving customized drugs and medical treatments for patients with rare or hard-to-treat diseases, as reported by the Associated Press.
The FDA is proposing a “plausible mechanism pathway” for approval of these treatments, particularly gene-editing therapies, according to reporting from STAT News. This pathway is expected to require evidence demonstrating a biologically plausible mechanism of action, even with limited clinical data.
The agency’s initiative builds on existing incentives for rare disease drug development, such as priority review vouchers awarded under section 529 for certain rare pediatric disease product applications, as outlined in FDA guidance documents.
